IsoRay Announces New Russian and Peruvian International Distributor Agreements for the Sale of IsoRay's Full Line of Products
June 20 2014 - 8:45AM
Marketwired
IsoRay Announces New Russian and Peruvian International Distributor
Agreements for the Sale of IsoRay's Full Line of Products
RICHLAND, WA--(Marketwired - Jun 20, 2014) - IsoRay, Inc.
(NYSEMKT: ISR) (http://www.isoray.com/), announced today that it
has entered into two (2) international distribution agreements: the
first with MedikorPharma-Ural LLC for the Russian market and the
other with Surgicorp SRL for the Peruvian market. IsoRay is a
medical technology company and innovator in seed brachytherapy and
medical radioisotope applications for brain cancer, lung cancer,
head and neck cancer, prostate cancer and gynecologic ("gyn")
cancer.
MedikorPharma and Surgicorp SRL both now have the right to
distribute all of IsoRay's products within their countries.
Together with IsoRay's other international distributors,
MedikorPharma and Surgicorp SRL are expected to support IsoRay's
long term goals by obtaining increased recognition in the world
marketplace for Cesium-131. IsoRay's Cesium-131 products utilize
the uniqueness of IsoRay's Cesium-131 isotope to attack cancers in
the prostate and other body sites, such as brain cancer, head and
neck cancer, lung cancer and gynecological cancers, while providing
patients with a better quality of life than many competing
treatments. IsoRay's continued success story will be accelerated as
more physicians and surgeons in the US and internationally are made
aware of the power of Cesium-131 through published studies
reporting positive patient outcomes from treatment with IsoRay
products.
IsoRay Chairman and CEO Dwight Babcock commented, "We are very
optimistic about achieving growth in adoption of our growing array
of new products and look to the international market to contribute
in the future as IsoRay's products receive the additional foreign
regulatory approvals and licenses needed for the sale of our
products in additional countries. All of our products, except our
just announced liquid Cesium-131 (Cesitrex®) for use in our
GliaSite® Radiation Therapy System, currently carry the CE Mark,
making them eligible to be sold in 31 European nations. Physicians
and institutions throughout the US are continuing to report
outstanding results in the use of our Cesium-131 seeds for brain
cancer, head and neck cancer, prostate cancer, lung cancer and
gynecological cancers. Given this growing acceptance and interest,
we remain committed to our strategic national and international
marketing objectives and believe this will contribute to our long
term success."
The Company is actively bringing new brachytherapy applications
to market, providing new solutions to leading physicians throughout
the world. The Company's continued investment in research and
development focusing on Cesium-131's efficacy for treatment of
various cancers located throughout the body is expected to have a
direct impact on its overall growth with an expanding array of
non-prostate cancer treatments. In addition, the recent
reorganization and increase in the size and quality of IsoRay's
sales organization in the US market has created the means to
contact more facilities than ever before with the Company's new and
novel treatment alternatives.
About IsoRay IsoRay, Inc., through its subsidiary, IsoRay
Medical, Inc., is the sole producer of Cesium-131 brachytherapy
seeds, which is expanding brachytherapy options throughout the
body. Learn more about this innovative Richland, Washington company
and explore the many benefits and uses of GliaSite® and Cesium-131
by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us
on Twitter@Isoray.
Safe Harbor Statement Statements in this news release about
IsoRay's future expectations, including: the advantages of our
products and their delivery systems, whether sales of our products
both in the U.S. and internationally will continue at historic
levels, decrease or increase, whether the use of our products will
increase or continue, whether future studies of treatment of
various cancers using our products will have favorable results,
whether awareness of our products in the medical community will
continue or increase, future demand for IsoRay's existing and
planned products, whether regulatory approvals and licenses will be
obtained or maintained in foreign countries, whether IsoRay will be
able to continue to expand its base beyond prostate cancer, whether
additional studies will be published with favorable outcomes from
treatment with our products, whether IsoRay's sales and marketing
and research and development efforts will contribute to growth,
whether new products will be developed and if so whether they will
be adopted by physicians, and all other statements in this release,
other than historical facts, are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 ("PSLRA"). This statement is included for the express
purpose of availing IsoRay, Inc. of the protections of the safe
harbor provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
physician acceptance, training and use of IsoRay's products,
changing levels of demand for IsoRay's current and proposed future
products, IsoRay's ability to reduce or maintain expenses while
increasing sales, whether additional studies are released and
support the conclusions of past studies, patient results achieved
with our products, successful completion of future research and
development activities, our ability of our distributors and
customers to receive and maintain all required regulatory approvals
in the U.S. and internationally, continued compliance with ISO
standards as audited by BSI, the success of our sales and marketing
efforts, IsoRay's ability to successfully manufacture, market and
sell its products, whether institutions will receive all required
state, federal and foreign regulatory approvals and licenses to use
IsoRay's products, IsoRay's ability to manufacture its products in
sufficient quantities to meet demand within required delivery time
periods while meeting its quality control standards, IsoRay's
ability to enforce its intellectual property rights, changes in
reimbursement rates, changes in laws and regulations applicable to
our products, and other risks detailed from time to time in
IsoRay's reports filed with the SEC.
CONTACT: IsoRay Medical Info@Isoray.com (509) 375-1202 Or
Worldwide Financial Info@wwfinancial.com (954) 360-9998
IsoRay (AMEX:ISR)
Historical Stock Chart
From Mar 2024 to Apr 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Apr 2023 to Apr 2024